Nyrada Inc – Brain Injury Program GLP Studies Further Update 6

Highlights:
• In vivo micronucleus study completed providing further data to support safety of Nyrada’s
lead Brain Injury drug candidate NYR-BI03.
• Study was completed under Good Laboratory Practice (GLP) conditions.
• Nyrada remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in
late CY2024.